3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
79
Triple Negative Breast Neoplasms
9
Stomach Neoplasms
8
Inflammatory Breast Neoplasms
6
Carcinoma, Hepatocellular
6
Non-Muscle Invasive Bladder Neoplasms
3
Esophageal Neoplasms
3
Sarcoma
2
Primary Breast Cancer
2
Pathologic Complete Response
2
Lung Neoplasms
2
Carcinoma, Ductal, Breast
2
Breast Neoplasms, Male
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdomyosarcoma
1
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oesophago-gastric Cancer
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Malignant mesenchymal tumor
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Interventions
Panitumumab
1
Oxaliplatin
1
Epirubicin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Oesophago-gastric Cancer
×
Epirubicin
×
Clear all
NCT00824785
2012-12-11
REAL3
Royal Marsden NHS Foundation Trust
Phase 3
Terminated
574 enrolled